Carregant...
RTHP-13. TUMOR-TREATING FIELDS THERAPY IS COMPATIBLE WITH STANDARD CHEMORADIOTHERAPY FOR GLIOBLASTOMA
PURPOSE: The phase III EF-14 trial demonstrated a significant overall survival benefit in 695 patients with glioblastoma who received adjuvant anti-mitotic tumor-treating fields (TTFields) therapy in addition to temozolomide (TMZ), following standard concurrent radiotherapy (RT) and TMZ. Preclinical...
Guardat en:
| Publicat a: | Neuro Oncol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217548/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.945 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|